TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Natumin Pharma AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
6,104
|
5,907
|
6,079 |
| Financial expenses |
99
|
46
|
37 |
| Earnings before taxes |
177
|
-359
|
-786 |
| EBITDA |
-67
|
-234
|
-601 |
| Total assets |
5,527
|
4,934
|
5,025 |
| Current assets |
3,496
|
3,383
|
3,276 |
| Current liabilities |
1,694
|
2,087
|
2,022 |
| Equity capital |
2,375
|
1,758
|
2,304 |
| - share capital |
180
|
180
|
196 |
| Employees (average) |
22
|
23
|
24 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
43.0%
|
35.6%
|
45.9% |
| Turnover per employee |
277
|
257
|
253 |
| Profit as a percentage of turnover |
2.9%
|
-6.1%
|
-12.9% |
| Return on assets (ROA) |
5.0%
|
-6.3%
|
-14.9% |
| Current ratio |
206.4%
|
162.1%
|
162.0% |
| Return on equity (ROE) |
7.5%
|
-20.4%
|
-34.1% |
| Change turnover |
180
|
320
|
287 |
| Change turnover % |
3%
|
6%
|
5% |
| Chg. No. of employees |
-1
|
-1
|
-1 |
| Chg. No. of employees % |
-4%
|
-4%
|
-4% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.